

Effect of Genetic Variants, Especially *CYP2C9* and *VKORC1*, on the Pharmacology of Warfarin

Erik Fung, MB, ChB, PhD^{1,2} Nikolaos A. Patsopoulos, MD, PhD^{3,4,5} Steven M. Belknap, MD⁶
 Daniel J. O'Rourke, MD^{1,2,7} John F. Robb, MD^{1,2} Jeffrey L. Anderson, MD^{8,9}
 Nicholas W. Shworak, MD, PhD^{1,2,10} Jason H. Moore, PhD^{2,11,12}

¹ Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire

² Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

³ Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

⁴ Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts

⁵ Broad Institute of Harvard and MIT, Cambridge, Massachusetts

⁶ Department of Medicine, Northwestern Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois

⁷ Section of Cardiology, Veterans Affairs Medical Center, White River Junction, Vermont

⁸ Cardiovascular Department, Intermountain Medical Center, Murray, Utah

⁹ University of Utah School of Medicine, Salt Lake City, Utah

¹⁰ Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

¹¹ Institute of Quantitative Biomedical Science, Dartmouth College, Hanover, New Hampshire

¹² Departments of Genetics and Community and Family Medicine, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, New Hampshire

Address for correspondence and reprint requests Erik Fung, MB, ChB, PhD, Section of Cardiology, Heart & Vascular Center, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, New Hampshire 03756 (e-mail: erik.fung@hitchcock.org).

Semin Thromb Hemost 2013;39:112.

The publisher regrets an error in a sentence in the above article in *Seminars in Thrombosis & Hemostasis*, Volume 38, Number 8, p. 900. The correct sentence is as below:
 In the latest prospective, clinical effectiveness trial, pharmacogenetic guidance was found to decrease the OOR INR by 12%.¹⁷